Harvard Bioscience Inc（HBIO）财务数据HBIOHarvard Bioscience Inc

Harvard Bioscience Inc (HBIO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Instruments, equipment, software and accessories, accounting for 89.5% of total sales, equivalent to $18.57M. Another important revenue stream is Service, maintenance and warranty contracts. Understanding this composition is critical for investors evaluating how HBIO navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Harvard Bioscience Inc maintains a gross margin of 51.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.90%, while the net margin is -12.80%. These profitability ratios, combined with a Return on Equity (ROE) of -89.95%, provide a clear picture of how effectively HBIO converts its operational activities into shareholder value.

In the context of the broader market, HBIO competes directly with industry leaders such as XTNT and DAVI. With a market capitalization of $38.02M, it holds a significant position in the sector. When comparing efficiency, HBIO's gross margin of 51.96% stands against XTNT's 57.88% and DAVI's N/A. Such benchmarking helps identify whether Harvard Bioscience Inc is trading at a premium or discount relative to its financial performance.

Harvard Bioscience reported Q2 2026 revenue of $22.7 million, an 11% year-over-year increase, but also a net loss of $2.9 million, widening from previous losses. The gross margin was 55.6%, slightly down from 56.4% last year, showing some pressure on profitability.